Trial
NCT04479904
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Intrahepatic Cholangiocarcinoma
Intervention
Famitinib
Why stopped
It is difficult to screening subject
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-22